Motive Therapeutics is engineering context-responsive mRNA circuits that activate only in disease — enabling precision therapies for autoimmune conditions with selectivity that today's treatments cannot approach.
The Problem
The $250B autoimmune market is built on broad immunosuppression. These therapies work — but at a profound cost. They cannot distinguish a disease flare from remission, or an immune cell driving inflammation from one fighting infection.
The result: 50 million patients in managed decline. The best available outcome is tolerance of side effects. No approved therapy offers a path off treatment.
Context-blind platforms overshoot — leaving patients exposed to infections, secondary cancers, and organ damage alongside their disease.
Unable to sense disease state, therapies remain active in remission — generating immune disruption in the very environments they're meant to correct.
By targeting downstream symptoms rather than the origin of autoimmune activation, current standards cannot offer patients a path off treatment.
The Platform
Motive's platform encodes therapeutic logic directly into the mRNA molecule — creating medicines that remain inert in healthy tissue and activate only in the cellular environments that define disease. Selectivity isn't layered on top. It's the architecture.
The sensor reads intracellular protein signatures — markers expressed only in disease-state cells — to determine whether the therapeutic should engage.
The controller gates translation based on sensor input. In healthy cells: silence. In disease cells: activation. This OFF-to-ON logic is the heart of Motive's IP.
Potent immune-modulating payloads are expressed precisely — in the right cells, at the right moment — dramatically widening the therapeutic window.
Biology communicates in proteins. Motive is the only platform that reads protein-level disease state to gate therapeutic expression — not RNA proxies or delivery alone.
Therapies remain inert until activated by disease-specific cellular context. No expression in off-target tissue — by design, not by chance.
Compatible with standard LNP delivery systems. Motive's platform integrates with existing infrastructure rather than requiring proprietary delivery technology.
Traction
At pre-seed, validation is proof. Motive's science and team have been independently evaluated by some of the most rigorous reviewers in biotechnology and federal research.
Actively discussing potential research collaborations with multiple top-10 global biopharmas — independent recognition of the platform's differentiation and strategic fit for next-generation pipeline development.
Pharma EngagementScored in the top percentile of federal peer review. Independent reviewers described the platform as "potentially transformative." Innovation scored 1–2 across all reviewers across two submission rounds.
Federal Peer ReviewAccepted into the Spring 2026 cohort of Blueprint by The Engine — MIT's deep tech venture program for companies at the frontier of what's possible.
Spring 2026 CohortTeam
Motive was founded by Caltech PhD classmates with over 20 years of scientific partnership before company formation — combining academic invention with the industry experience required to take it to the clinic.
Contact
We're actively engaging investors who share our conviction that the next generation of autoimmune medicine will be built on precision, not suppression.
Thanks — we'll be in touch shortly.